Hidehito Horinouchi, Assistant Chief of the National Cancer Center Hospital, shared a post on X about a recent paper by Fabio Conforti et al. published in the Journal of Clinical Oncology:
“Surrogate End Points for Overall Survival in Neoadjuvant Randomized Clinical Trials for Early Breast Cancer.
iDFS is an acceptable surrogate endpoint to confidently anticipate the final OS.
Dr. Fabio Conforti.”
Authors: Fabio Conforti, Valentina Nekljudova, Isabella Sala, Richard Gelber, Sibylle Loibl et al.
More posts featuring Hidehito Horinouchi.